|1.||Biggar, W Douglas: 4 articles (06/2013 - 03/2004)|
|2.||Biggar, W D: 4 articles (12/2012 - 01/2001)|
|3.||Hodson, E M: 4 articles (01/2004 - 01/2000)|
|4.||Willis, N S: 4 articles (01/2004 - 01/2000)|
|5.||Craig, J C: 4 articles (01/2004 - 01/2000)|
|6.||Knight, J F: 4 articles (01/2004 - 01/2000)|
|7.||Alman, Benjamin A: 3 articles (06/2013 - 03/2004)|
|8.||Harris, V A: 3 articles (04/2006 - 01/2001)|
|9.||Santo Neto, Humberto: 2 articles (07/2015 - 09/2009)|
|10.||Marques, Maria Julia: 2 articles (07/2015 - 09/2009)|
|1.||Nephrotic Syndrome (Syndrome, Nephrotic)
04/01/2015 - "This study was done to compare the effectiveness and safety of deflazacort in idiopathic nephrotic syndrome. "
08/01/1997 - "A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome."
01/01/2004 - "In children with frequently relapsing nephrotic syndrome, deflazacort was significantly more effective in maintaining remission than prednisone (RR 0.44; 95% CI 0.25 to 0.78). "
01/01/2003 - "In children with frequently relapsing nephrotic syndrome, deflazacort was significantly more effective in maintaining remission than prednisone (RR 0.44; 95% CI 0.25 to 0.78). "
01/01/2001 - "In children with frequently relapsing nephrotic syndrome, deflazacort was significantly more effective in maintaining remission than prednisone (RR 0.44; 95% CI 0.25, 0.78). "
|2.||Asthma (Bronchial Asthma)
09/01/2004 - "Deflazacort and prednisolone show similar efficacy in improving pulmonary function and in producing clinical improvement in the management of acute moderate asthma in children."
09/01/2004 - "[Comparative efficacy of oral deflazacort versus oral prednisolone in children with moderate acute asthma]."
10/01/2007 - "Twelve patients were enrolled, all of whom were allergic to Parietaria judaica and suffering for mild persistent asthma: six were treated with desloratadine (10 mg/day), and six with deflazacort (12 mg/day). "
09/01/2004 - "To assess the efficacy and tolerability of oral deflazacort versus oral prednisolone in acute moderate asthma in children. "
07/01/1995 - "The purpose of this study was to compare the efficacy of deflazacort and prednisone as anti-inflammatory agents capable of controlling severe asthma crisis in addition to analyzing their side effects. "
09/01/1999 - "deflazacort seems to be useful in maintaining remission of autoimmune hepatitis during a prolonged period of follow-up. "
09/01/1999 - "Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis."
08/01/2006 - "Deflazacort for type-1 autoimmune hepatitis in a Korean girl."
09/01/1999 - "The aim of this study was to evaluate the efficacy of deflazacort, an oxazolinic derivative of prednisolone with fewer effects on bone and glucose metabolism, in the maintenance of remission of type I autoimmune hepatitis in patients treated previously with conventional immunosuppressive therapy. "
08/01/2006 - "An 11-yr-old Korean girl with type-1 autoimmune hepatitis discontinued prednisolone due to toxicities, i.e., hirsutism, buffalo hump, and skin striae, and remained clinical and biochemical remission under replacement of deflazacort and ursodeoxycholic acid combination therapy. "
10/01/2007 - "They are probably equally effective in stabilizing muscle strength but may have different side-effect profiles; for instance, deflazacort causes less weight gain. "
04/01/2015 - "Deflazacort is an oxazoline derivative and preliminary data suggest reduced osteoporosis, lesser growth retardation and weight gain with deflazacort. "
10/01/2009 - "Preliminary data suggest reduced osteoporosis, lesser growth retardation and weight gain with use of deflazacort, as compared to other steriods. "
09/01/2000 - "Steroid treatment with deflazacort appears to cause fewer side effects than with prednisone, particularly weight gain, which could be important to maximize motor performances."
08/31/1992 - "A very simple, low dose, orally administered regime (10 to 15 mg of fluoximesterone + 6 mg of deflazacort daily for periods of 1 to several months) resulting in mild-acceptable toxicity (essentially some weight gain) determined subjective improvement in 2/3 of 34 evaluable patients (out of 36 treated) and an objective measurable tumor reduction in 1/3, although most patients had been previously treated with chemotherapy and hormone treatment and proved primarily or secondarily refractory. "
|5.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
08/01/1995 - "Insufficient data are available to draw firm conclusions regarding the efficacy of deflazacort as treatment for patients with severe asthma, but the drug has demonstrated some efficacy as treatment for nephrotic syndrome and other applications such as Duchenne dystrophy, systemic lupus erythematosus, uveitis and transplantation. "
01/01/1993 - "In this paper, the therapeutic efficacy of two glucocorticoids, deflazacort (DFZ) and prednisone (PDN), are discussed in relation to a group of 30 patients with systemic lupus erythematosus (n = 12) or rheumatoid arthritis (n = 18). "
|4.||Adrenal Cortex Hormones (Corticosteroids)
|1.||Transplantation (Transplant Recipients)
|2.||Lithotripsy (Extracorporeal Shockwave Lithotripsy)
|3.||Drug Therapy (Chemotherapy)
|5.||Palliative Care (Palliative Medicine)